Grace Therapeutics' NDA for Lead Candidate GTx-104 Accepted by FDA with April 2026 PDUFA Date; Raises $4.04M from Warrant Exercises

summarizeSummary

Grace Therapeutics announced FDA acceptance of its NDA for lead candidate GTx-104 with an April 2026 PDUFA date, secured a new patent, and raised $4.04 million from warrant exercises, extending its cash runway to over 12 months.

check_boxKey Events

• FDA Accepts NDA for Lead Candidate GTx-104

  The FDA accepted the New Drug Application (NDA) for GTx-104, the company's lead injectable formulation for aneurysmal subarachnoid hemorrhage (aSAH), for review on August 22, 2025.

• PDUFA Target Date Set for April 2026

  The FDA has set April 23, 2026, as the Prescription Drug User Fee Act (PDUFA) target date for completing its review of the GTx-104 NDA.

• New Patent Issued for GTx-104

  A new U.S. Patent (No. 12,414,943) was issued in September 2025, covering the IV dosing regimen for GTx-104 and extending intellectual property protection to 2043.

• Raises $4.04 Million from Warrant Exercises

  In October 2025, the company received $4.04 million in gross proceeds from the exercise of 1,345,464 common warrants issued in a September 2023 private placement. The remaining 1,190,927 warrants from that placement expired.

auto_awesomeAnalysis

This quarterly report highlights significant progress for Grace Therapeutics' lead drug candidate, GTx-104, with the FDA accepting its New Drug Application (NDA) for review and setting an April 23, 2026 PDUFA target date. This is a critical de-risking event for a development-stage biotech, providing a clear timeline for potential market entry. The company also strengthened its intellectual property with a new patent for GTx-104 extending protection to 2043. Furthermore, the exercise of common warrants generated $4.04 million in gross proceeds, significantly bolstering liquidity and contributing to a projected cash runway of at least 12 months. While the company continues to incur operating losses and has established a partial valuation allowance against deferred tax assets (indicating management's uncertainty about future taxable income), the advancement of GTx-104 and the capital infusion are substantial positive developments for the company's near-term outlook.